Metabolic Reprogramming in Deep Vein Thrombosis: A Novel Therapeutic Avenue Beyond Anticoagulation
Flora Peyvandi, Professor of Internal Medicine at the University of Milan and former president of ISTH, recently shared an honoring post on X:
”Metabolic pathways in deep vein thrombosis: a new frontier for therapeutic intervention. This is a fascinating paper. Congratulations to the authors!”
Read the full article here.
Traditional anticoagulants do their job well—until they start doing it a little too well, turning the prevention of clots into a new risk: bleeding, especially when you need them the most over time.
In the new study published by Ivan Budnik et al. in Blood Journal by American Society of Hematology (ASH), metabolic pathways responsible for clot formation are seen as alternatives for treatment focus.
Preclinical studies reveal that targeting metabolic pathways can reduce thrombus formation without compromising hemostasis.
This metabolism-focused paradigm offers promising therapeutic potential, aiming to prevent or mitigate DVT while minimizing bleeding risk, and underscores the need for translational research into metabolic interventions as adjuncts or alternatives to anticoagulants.
Hemostasis Today, your daily update on scientific advancements in thrombosis and hemostasis field.
-
Jan 16, 2026, 06:05Wolfgang Miesbach on Jacob Lund’s Study: How to Define FVIII Bioequivalence
-
Jan 16, 2026, 05:52Piotr Czempik Shares His Latest Contribution to Acta Haematologica Polonic
-
Jan 16, 2026, 05:44Florian Piekarski on Perioperative Blood Management When Allogeneic Transfusion is Not Aaccepted
-
Jan 16, 2026, 05:00Plaque Rupture and Thrombosis
-
Jan 16, 2026, 04:52Arterial Disease Across Vascular Beds․ Lipoprotein(a) as a Causal Risk Factor
-
Jan 16, 2026, 04:51Higher-Dose Clotting Factor Prophylaxis Does Not Reduce Postpartum Hemorrhage in Women with von Willebrand Disease
-
Jan 16, 2026, 04:48Reza Shojaei on Plasma Donation as Life-Changing Medicine in Motion
-
Jan 16, 2026, 04:11Open-Label Extension Study of Marstacimab: Pfizer Has Reported a Fatal Event
-
Jan 16, 2026, 04:11Why is DVT More Common In the Left Leg? Dr Raheel Moazzam’s New Study Gives Answers!